Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, randomized, two-arm, phase II clinical trial to evaluate
the efficacy and safety of talazoparib (PF-06944076) in combination with enzalutamide in
patients with metastatic hormone-naïve prostate cancer (mHNPC)